دورية أكاديمية
Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium.
العنوان: | Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium. |
---|---|
المؤلفون: | Benefield HC; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Zirpoli GR; Slone Epidemiology Center at Boston University, Boston, Massachusetts., Allott EH; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom., Shan Y; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Hurson AN; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Omilian AR; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Khoury T; Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York., Hong CC; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Olshan AF; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Bethea TN; Slone Epidemiology Center at Boston University, Boston, Massachusetts., Bandera EV; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Palmer JR; Slone Epidemiology Center at Boston University, Boston, Massachusetts., Ambrosone CB; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Troester MA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. troester@unc.edu. |
المصدر: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2021 Jan; Vol. 30 (1), pp. 71-79. Date of Electronic Publication: 2020 Oct 23. |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7755 (Electronic) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991- |
مواضيع طبية MeSH: | Breast Neoplasms/*ethnology , Receptor, ErbB-2/*genetics , Receptors, Estrogen/*genetics , Receptors, Progesterone/*genetics, Black or African American/statistics & numerical data ; Breast Neoplasms/genetics ; Female ; Humans ; Risk Factors ; Triple Negative Breast Neoplasms/ethnology |
مستخلص: | Background: Evidence suggests etiologic heterogeneity among breast cancer subtypes. Previous studies with six-marker IHC classification of intrinsic subtypes included small numbers of black women. Methods: Using centralized laboratory results for estrogen receptor (ER), progesterone receptor, HER2, proliferation marker, Ki-67, EGFR, and cytokeratin (CK)5/6, we estimated case-only and case-control ORs for established breast cancer risk factors among cases ( n = 2,354) and controls ( n = 2,932) in the African American Breast Cancer Epidemiology and Risk (AMBER) consortium. ORs were estimated by ER status and intrinsic subtype using adjusted logistic regression. Results: Case-only analyses by ER status showed etiologic heterogeneity by age at menarche, parity (vs. nulliparity), and age at first birth. In case-control analyses for intrinsic subtype, increased body mass index and waist-to-hip ratio (WHR) were associated with increased risk of luminal A subtype, whereas older age at menarche and parity, regardless of breastfeeding, were associated with reduced risk. For basal-like cancers, parity without breastfeeding and increasing WHR were associated with increased risk, whereas breastfeeding and age ≥25 years at first birth were associated with reduced risk among parous women. Basal-like and ER - /HER2 + subtypes had earlier age-at-incidence distribution relative to luminal subtypes. Conclusions: Breast cancer subtypes showed distinct etiologic profiles in the AMBER consortium, a study of more than 5,000 black women with centrally assessed tumor biospecimens. Impact: Among black women, high WHR and parity without breastfeeding are emerging as important intervention points to reduce the incidence of basal-like breast cancer. (©2020 American Association for Cancer Research.) |
References: | J Natl Cancer Inst. 2015 Apr 28;107(7):. (PMID: 25921910) Breast Cancer Res Treat. 2013 Jan;137(2):579-87. (PMID: 23224237) Breast Cancer Res Treat. 2014 Apr;144(3):689-99. (PMID: 24604094) J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204) Breast Cancer Res Treat. 2015 Apr;150(3):655-66. (PMID: 25809092) Biostatistics. 2008 Jan;9(1):137-51. (PMID: 17566074) Breast Cancer Res Treat. 1995 Jul;35(1):51-60. (PMID: 7612904) Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729. (PMID: 28903991) Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):270-277. (PMID: 27756774) Breast Cancer Res. 2018 Jan 22;20(1):5. (PMID: 29357906) J Natl Cancer Inst. 2014 Aug 12;106(8):. (PMID: 25118203) J Oncol. 2009;2009:871250. (PMID: 19865486) Breast Cancer Res. 2017 Jan 13;19(1):6. (PMID: 28086982) Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1899-905. (PMID: 17035397) Cancer Causes Control. 2014 Mar;25(3):309-19. (PMID: 24343304) Adv Nutr. 2015 Nov 13;6(6):803-19. (PMID: 26567202) Medicine (Baltimore). 2016 Apr;95(14):e3063. (PMID: 27057831) Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1437-42. (PMID: 17627009) Breast Cancer Res Treat. 2008 May;109(1):123-39. (PMID: 17578664) Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1297-304. (PMID: 27307466) J Natl Cancer Inst. 2014 Sep 15;106(10):. (PMID: 25224496) Ann Oncol. 2013 Sep;24(9):2206-23. (PMID: 23917950) Cancer Res. 2017 Jul 1;77(13):3708-3717. (PMID: 28512241) Int J Cancer. 2016 May 15;138(10):2346-56. (PMID: 26684063) Breast Cancer Res Treat. 2012 Jan;131(1):159-67. (PMID: 21830014) Clin Cancer Res. 2004 Aug 15;10(16):5367-74. (PMID: 15328174) Cancer Res. 2018 Oct 15;78(20):6011-6021. (PMID: 30185547) Breast Cancer Res. 2009;11(3):R31. (PMID: 19463150) Climacteric. 2012 Feb;15(1):68-74. (PMID: 22132797) Breast Cancer Res Treat. 2013 Nov;142(1):165-75. (PMID: 24136668) Breast Cancer Res. 2009;11(2):R18. (PMID: 19320967) Breast Cancer Res. 2019 Mar 12;21(1):40. (PMID: 30867002) BMC Med Res Methodol. 2013 May 31;13:71. (PMID: 23721229) MMWR Morb Mortal Wkly Rep. 2013 Feb 8;62(5):77-80. (PMID: 23388550) Cancer Causes Control. 2009 Sep;20(7):1071-82. (PMID: 19343511) BMC Med Genomics. 2012 Oct 04;5:44. (PMID: 23035882) J Am Med Womens Assoc (1972). 1995 Mar-Apr;50(2):56-8. (PMID: 7722208) Cancer Causes Control. 2014 Feb;25(2):259-65. (PMID: 24249438) Am J Epidemiol. 2000 Feb 15;151(4):346-57. (PMID: 10695593) Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):454-63. (PMID: 21364029) Clin Cancer Res. 2010 Nov 1;16(21):5222-32. (PMID: 20837693) Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):413-9. (PMID: 10350436) Cancer. 2012 Nov 15;118(22):5463-72. (PMID: 22544643) Breast Cancer Res. 2015 Feb 21;17:22. (PMID: 25849024) J Natl Cancer Inst. 2015 Jun 17;107(9):. (PMID: 26085483) Breast Cancer Res. 2018 Feb 06;20(1):12. (PMID: 29409530) Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):725-34. (PMID: 24521998) Am J Epidemiol. 1996 Aug 1;144(3):207-13. (PMID: 8686689) Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1883-91. (PMID: 21846820) Breast Cancer Res Treat. 2020 Jan;179(1):185-195. (PMID: 31535320) Cancer. 2010 Nov 1;116(21):4933-43. (PMID: 20665494) Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):470-8. (PMID: 26711328) Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):714-24. (PMID: 24521995) JAMA. 2006 Jun 7;295(21):2492-502. (PMID: 16757721) Ann Oncol. 2015 Dec;26(12):2398-407. (PMID: 26504151) J Clin Oncol. 2008 Mar 10;26(8):1275-81. (PMID: 18250347) |
معلومات مُعتمدة: | U01 CA179715 United States CA NCI NIH HHS; K01 CA212056 United States CA NCI NIH HHS; P30 ES010126 United States ES NIEHS NIH HHS; P30 CA016056 United States CA NCI NIH HHS; P01 CA151135 United States CA NCI NIH HHS; P30 CA016086 United States CA NCI NIH HHS; P50 CA058223 United States CA NCI NIH HHS; R01 CA058420 United States CA NCI NIH HHS; F30 CA236199 United States CA NCI NIH HHS; R01 CA100598 United States CA NCI NIH HHS; U01 CA164974 United States CA NCI NIH HHS; R01 CA098663 United States CA NCI NIH HHS; UM1 CA164974 United States CA NCI NIH HHS; T32 CA057726 United States CA NCI NIH HHS |
المشرفين على المادة: | 0 (Receptors, Estrogen) 0 (Receptors, Progesterone) EC 2.7.10.1 (Receptor, ErbB-2) |
تواريخ الأحداث: | Date Created: 20201024 Date Completed: 20211126 Latest Revision: 20240607 |
رمز التحديث: | 20240607 |
مُعرف محوري في PubMed: | PMC8935955 |
DOI: | 10.1158/1055-9965.EPI-20-0556 |
PMID: | 33097496 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1538-7755 |
---|---|
DOI: | 10.1158/1055-9965.EPI-20-0556 |